Allavena C - Search Results

1

Sport and self-esteem in people living with HIV: a cross-sectional study.

Grandiere Perez L, Allavena C, Sécher S, Durand S, Grégoire A, Vandamme YM, Hitoto H, Leautez-Nainville S, Michau C, Billaud E. Grandiere Perez L, et al. Among authors: allavena c. BMC Infect Dis. 2022 Nov 17;22(1):858. doi: 10.1186/s12879-022-07860-y. BMC Infect Dis. 2022. PMID: 36396982 Free PMC article.

2

[Experience with nevirapine taken once daily in 93 HIV-infected patients].

Allavena C, François C, Reliquet V, Perre P, Michau C, Peytavin G, Raffi F. Allavena C, et al. Pathol Biol (Paris). 1999 May;47(5):563-5. Pathol Biol (Paris). 1999. PMID: 10418041 Clinical Trial. French.

3

Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.

Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Allavena C, et al. Antivir Ther. 2006;11(2):263-5. Antivir Ther. 2006. PMID: 16640107

4

Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).

Allavena C, Prazuck T, Reliquet V, Verdon R, Perré P, Le Moal G, Billaud E, Raffi F. Allavena C, et al. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug;7(4):187-92. doi: 10.1177/1545109708322015. Epub 2008 Jul 3. J Int Assoc Physicians AIDS Care (Chic). 2008. PMID: 18599881

5

The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope.

Pacheco Y, Allavena C, Guilloux Y, Mueller-Schmucker SM, Hueckelhoven AG, André-Garnier E, Cleon F, Ferré V, Rodallec A, Billaud E, Harrer T, Raffi F, McIlroy D. Pacheco Y, et al. Among authors: allavena c. J Clin Immunol. 2011 Aug;31(4):681-9. doi: 10.1007/s10875-011-9520-z. Epub 2011 Apr 14. J Clin Immunol. 2011. PMID: 21491096

6

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.

Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P. Dailly E, et al. Among authors: allavena c. Fundam Clin Pharmacol. 2012 Aug;26(4):538-42. doi: 10.1111/j.1472-8206.2011.00949.x. Epub 2011 May 5. Fundam Clin Pharmacol. 2012. PMID: 21545648

7

Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI.

Pacheco Y, Solé V, Billaud E, Allavena C, Plet A, Ferré V, Garrigue-Antar L, Raffi F, Jacques Y, McIlroy D. Pacheco Y, et al. Among authors: allavena c. AIDS. 2011 Sep 10;25(14):1701-10. doi: 10.1097/QAD.0b013e328349a437. AIDS. 2011. PMID: 21673554

8

High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, Guillot P, Duvivier C, Billaud E, Raffi F. Allavena C, et al. J Antimicrob Chemother. 2012 Sep;67(9):2222-30. doi: 10.1093/jac/dks176. Epub 2012 May 15. J Antimicrob Chemother. 2012. PMID: 22589455

9

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.

10

Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.

Allavena C, Bach-Ngohou K, Billaud E, Sécher S, Dejoie T, Reliquet V, Fakhouri F, Raffi F. Allavena C, et al. J Antimicrob Chemother. 2013 Dec;68(12):2866-70. doi: 10.1093/jac/dkt265. Epub 2013 Jun 30. J Antimicrob Chemother. 2013. PMID: 23818285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters